{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:04:57Z","timestamp":1771603497639,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Epileptologica"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-leucine-rich glioma-inactivated 1 (LGI-1) autoimmune encephalitis (AE), characterized by rapid decline of memory, seizures, and neuropsychiatric abnormalities, is a rare but devastating disorder. Early diagnosis and treatment are essential to prevent long-term sequelae. In this report, we provide a detailed description of clinical characteristics, laboratory test results, imaging, and electroencephalography (EEG) findings, as well as treatment responses of eight patients with anti-LGI-1 AE treated at our center.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>At the onset, all eight patients presented with confusion\/memory deterioration, seizures (including faciobrachial dystonic seizures or other types of seizure), and behavioral changes such as hallucination, paranoia, and anxiety. Four patients were found with severe hyponatremia. Anti-LGI1 antibodies were detected in the cerebrospinal fluid and\/or serum of all patients. For patients with faciobrachial dystonic seizures, no discernible scalp EEG change was detected, while EEG recording of patients experiencing other types of seizure showed focal slowing, focal epileptiform discharges, and focal onset seizures. All patients showed abnormal brain magnetic resonance imaging signals, mainly involving the mesial temporal lobe and the hippocampus. In addition, one patient also experienced fulminant cerebral edema during the acute phase of the illness. All patients received immunotherapy and anti-seizure medications and achieved good seizure control. Nevertheless, these patients continued to experience cognitive impairment during their long-term follow-ups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The care of anti-LGI1 AE patients requires rapid evaluation, prompt initiation of immunotherapy, and long-term follow-up. The long-term presence of neurocognitive complications observed in these patients underline the importance of developing reliable biomarkers that can distinguish between different subtypes of this disease with heterogeneous clinico-electrographico-radiological features. Further research is needed to understand the molecular mechanisms underlying the heterogeneity, in order to facilitate development of more effective treatments for anti-LGI1 AE.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42494-023-00132-5","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T03:28:27Z","timestamp":1692070107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heterogeneity of clinical features, EEG and brain imaging findings in anti-leucine-rich glioma-inactivated protein 1 autoimmune encephalitis: a retrospective case series study and review of the literature"],"prefix":"10.1186","volume":"5","author":[{"given":"Emily Yixuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"132_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","volume":"89","author":"SNM Binks","year":"2018","unstructured":"Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry. 2018;89:526\u201334.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"132_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","volume":"9","author":"M Lai","year":"2010","unstructured":"Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. The Lancet Neurology. 2010;9:776\u201385.\u00a0","journal-title":"The Lancet Neurology"},{"key":"132_CR3","doi-asserted-by":"publisher","first-page":"577598","DOI":"10.1016\/j.jneuroim.2021.577598","volume":"357","author":"L Zuliani","year":"2021","unstructured":"Zuliani L, Marangoni S, De Gaspari P, Rosellini I, Nosadini M, Fleming JM, et al. Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics. J Neuroimmunology. 2021;357:577598.\u00a0","journal-title":"J Neuroimmunology."},{"key":"132_CR4","doi-asserted-by":"crossref","unstructured":"van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016;87(14):1449\u201356.","DOI":"10.1212\/WNL.0000000000003173"},{"key":"132_CR5","doi-asserted-by":"crossref","unstructured":"van Sonderen A, Schreurs MW, Wirtz PW, Sillevis Smitt PA, Titulaer MJ. From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time. Autoimmun Rev. 2016;15(10):970\u20134.","DOI":"10.1016\/j.autrev.2016.07.018"},{"key":"132_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92:757\u201368.\u00a0","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"132_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.25131","volume":"83","author":"D Dubey","year":"2018","unstructured":"Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis: autoimmune encephalitis. Ann Neurol. 2018;83:166\u201377.\u00a0","journal-title":"Ann Neurol"},{"key":"132_CR8","doi-asserted-by":"crossref","unstructured":"Teng Y, Li T, Yang Z, Su M, Ni J, Wei M, et al. Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review. Front Neurol. 2022;12:791014.","DOI":"10.3389\/fneur.2021.791014"},{"key":"132_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/practneurol-2020-002567","volume":"21","author":"CE Uy","year":"2021","unstructured":"Uy CE, Binks S, Irani SR. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol. 2021;21:412\u201323.\u00a0","journal-title":"Pract Neurol"},{"key":"132_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.yebeh.2017.08.011","volume":"77","author":"C Chen","year":"2017","unstructured":"Chen C, Wang X, Zhang C, Cui T, Shi W-X, Guan H-Z, et al. Seizure semiology in leucine-rich glioma-inactivated protein 1 antibody-associated limbic encephalitis. Epilepsy Behav. 2017;77:90\u20135.\u00a0","journal-title":"Epilepsy Behav"},{"key":"132_CR11","doi-asserted-by":"crossref","unstructured":"Roberto KT, Espiritu AI, Fernandez MLL, Gutierrez JC. Electroencephalographic findings in antileucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis: A systematic review. Epilepsy Behav. 2020;112:107462.","DOI":"10.1016\/j.yebeh.2020.107462"},{"key":"132_CR12","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1212\/NXI.0000000000001136","volume":"9","author":"E Rissanen","year":"2022","unstructured":"Rissanen E, Carter K, Cicero S, Ficke J, Kijewski M, Park M-A, et al. Cortical and subcortical dysmetabolism are dynamic markers of clinical disability and course in anti-LGI1 encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022;9(2):e1136.\u00a0","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"132_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fnins.2020.00304","volume":"14","author":"J Qiao","year":"2020","unstructured":"Qiao J, Zhao X, Wang S, Li A, Wang Z, Cao C, et al. Functional and structural brain alterations in encephalitis with LGI1 antibodies. Front Neurosci. 2020;14:304.\u00a0","journal-title":"Front Neurosci"},{"key":"132_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jns.2017.03.020","volume":"376","author":"M Szots","year":"2017","unstructured":"Szots M, Blaabjerg M, Orsi G, Iversen P, Kondziella D, Madsen CG, et al. Global brain atrophy and metabolic dysfunction in LGI1 encephalitis: a prospective multimodal MRI study. J Neurol Sci. 2017;376:159\u201365.\u00a0","journal-title":"J Neurol Sci"},{"key":"132_CR15","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1007\/s00415-022-11162-3","volume":"269","author":"D Guery","year":"2022","unstructured":"Guery D, Cousyn L, Navarro V, Picard G, Rogemond V, Bani-Sadr A, et al. Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies. J Neurol. 2022;269:5061\u20139.\u00a0","journal-title":"J Neurol"},{"key":"132_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaneurol.2016.4538","volume":"74","author":"GS Day","year":"2017","unstructured":"Day GS. Rethinking outcomes in leucine-rich, glioma-inactivated 1 protein encephalitis: \u201cGood\u201d isn\u2019t good enough. JAMA Neurol. 2017;74:19.\u00a0","journal-title":"JAMA Neurol"},{"key":"132_CR17","doi-asserted-by":"crossref","unstructured":"Finke C, Pr\u00fcss H, Heine J, Reuter S, Kopp UA, Wegner F, et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 Antibodies. JAMA Neurol. 2017;74(1):50\u20139.","DOI":"10.1001\/jamaneurol.2016.4226"},{"key":"132_CR18","doi-asserted-by":"crossref","unstructured":"Kegel L, Aunin E, Meijer D, Bermingham J.R. LGI proteins in the nervous system. ASN Neuro. 2013;5(3).","DOI":"10.1042\/AN20120095"},{"key":"132_CR19","doi-asserted-by":"crossref","unstructured":"Fels E, Mu\u00f1iz-Castrillo S, Vogrig A, Joubert B, Honnorat J, Pascual O. Role of LGI1 protein in synaptic transmission: From physiology to pathology. Neurobiol Dis. 2021;160:105537.","DOI":"10.1016\/j.nbd.2021.105537"},{"key":"132_CR20","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/brain\/awaa104","volume":"143","author":"M Ramberger","year":"2020","unstructured":"Ramberger M, Berretta A, Tan JMM, Sun B, Michael S, Yeo T, et al. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain. 2020;143:1731\u201345.\u00a0","journal-title":"Brain"},{"key":"132_CR21","doi-asserted-by":"publisher","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","volume":"33","author":"T Ohkawa","year":"2013","unstructured":"Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N, Takashima H, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci. 2013;33:18161\u201374.\u00a0","journal-title":"J Neurosci"},{"key":"132_CR22","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1093\/brain\/awy271","volume":"141","author":"D Debanne","year":"2018","unstructured":"Debanne D, El Far O. Pre- and postsynaptic effects of LGI1 autoantibodies in a murine model of limbic encephalitis. Brain. 2018;141:3092\u20135.\u00a0","journal-title":"Brain"},{"key":"132_CR23","doi-asserted-by":"crossref","unstructured":"Extr\u00e9met J, El Far O, Ankri N, Irani SR, Debanne D, Russier M. An epitope-specific LGI1-autoantibody enhances neuronal excitability by modulating Kv1.1 Channel. Cells. 2022;11(17):2713.","DOI":"10.3390\/cells11172713"},{"key":"132_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/cells12020282","volume":"12","author":"S Ludewig","year":"2023","unstructured":"Ludewig S, Salzburger L, Goihl A, Rohne J, Leypoldt F, Bittner D, D\u00fczel E, et al. Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis. Cells. 2023;12:282.\u00a0","journal-title":"Cells"}],"container-title":["Acta Epileptologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-023-00132-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42494-023-00132-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-023-00132-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T21:29:52Z","timestamp":1700256592000},"score":1,"resource":{"primary":{"URL":"https:\/\/aepi.biomedcentral.com\/articles\/10.1186\/s42494-023-00132-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1186\/s42494-023-00132-5","relation":{},"ISSN":["2524-4434"],"issn-type":[{"value":"2524-4434","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kaiser Permanente Medical Center. All patients or the patient\u2019s next-of-kin provided written informed consent to participate if a patient could not sign due to disability. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients or the next-of-kin of patients for publication of this research and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}